Morgans Under the Microscope

Healthcare analyst Iain Wilkie runs through a number of healthcare announcements over the week and recaps a few trading ideas which have performed strongly over the last few weeks.

Scott Power part of the Morgans Healthcare team provides an update on Volpara after successfully completing its capital raising.

Morgans Senior Analyst Derek Jellinek discusses RMD 3Q results and strong resilience shown across the core business and incremental gains from COVID-19 induced demand for ventilators.

Healthcare analyst Iain Wilkie runs through some market news, a number of updates for stocks under coverage, and some comments on the relaxation of a number of elective medical procedures announced over the week.

Morgans Senior Analyst Scott Power updates the network with information on 3 companies: Volpara (ASX:VHT), Impedimed (ASX:IPD) and Micro-X (ASX:MX1).

Morgans Research Analyst Iain Wilkie talks with Michelle Gallaher, CEO of Opyl Limited (#ASX : $OPL). Michelle gives a recap on a number of products coming to market, a new partner to expand its reach, and what potential investors can look out for.

Morgans Research Analyst Iain Wilkie talks with Mark Diamond, Managing Director of Antisense Therapeutics (ASX:ANP). Mark shares a recap on what the company does, and what potential investors can look out for.

Morgans Senior Analyst Scott Power, close out on the week that was 3/04/2020. He shares an update on the Healthcare sector and run through a couple of stocks to look out for.

Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 20/03/2020. They run through another tough week on the market, and provide an update on some of their stocks under coverage.

Morgans Analyst Iain Wilkie and Senior Analyst Scott Power, close out on the week that was 13/03/2020. They run through a number of announcements from over the week and share a market wrap on what was one of the sharpest weekly declines in recent years.